Glioblastoma Polymorphic

Glioblastomas are an aggressive brain tumor that arises from glial cells and tends to grow rapidly and spread throughout the brain. Glioblastomas can be found at any age, but they are most common in people over 50 years of age.

One of the most common forms of glioblastoma is glioblatoma multiforme (PMG). It is characterized by the presence of several cell types, including tumor cells, normal cells of glial origin, and healthy epithelial cells. This can lead to various symptoms such as headaches, dizziness, visual disturbances and other neurological symptoms.

RMZ arose about 6 million years ago - then a massive modification of cells occurred. At the same time, the “KIF20A” gene was in a mutating state, which provoked the pathogenesis of a tumor neoplasm capable of mutating and growing again. Ultimately, RMZ move into the stage of aggressive RRT, which is multifocal (multizonal), which accelerates the process of oncological damage.

The main treatment for glioblastoma is surgery. After tumor removal, chemotherapy and radiation therapy are performed. However, even with successful treatment, the risk of relapse remains high, so after completion of the main treatment it is necessary to continue monitoring with a doctor.

As for the prognosis, it depends on many factors, such as the stage of the disease, the type of tumor and the presence of metastases. If patients do not receive treatment, glioblastomas usually progress very quickly and lead to death within a few months. If treatment is started on time, the likelihood of survival increases significantly.

Thus, polymorphic glioblastomas require serious attention from medical professionals and patients. Timely treatment can improve the quality of life and prolong its duration.